Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Long non-coding RNA GAS5 inhibits migration and invasion in gastric cancer via interacting with p53 protein.
|
31530437 |
2020 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We systematically inspected missense mutations in TP53, from a TCGA (The Cancer Genome Atlas) GC dataset in UCSC Xena repository.
|
29994072 |
2020 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
More important, we discovered that VCAN-AS1 expression was negatively correlated with wild-type p53 levels in GC tissues and that p53 was negatively modulated by VCAN-AS1 in GC cells.
|
31637706 |
2020 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Epstein-Barr virus (EBV)-positive gastric cancers (GC) have clinicopathologic differences from EBV-negative tumors and lack TP53 mutation.
|
31719065 |
2020 |
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results demonstrated that PURPL RNA level in GC was significantly related to tumor size and histopathological grade. p53 expression at both protein and mRNA levels were significantly decreased in GC tissues compared to adjacent control samples.
|
31606380 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
XPO1 inhibition induced cell cycle arrest through p53 activation, but the mechanisms of p53 activation differed among the different types of cancer cells. p53 activation depended on the formation of promyelocytic leukemia (PML) nuclear bodies in gastric cancer and liver cancer cells.
|
31088931 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, LKB1 expression in GC was inversely associated with p53 (<i>r</i>=-0.181, <i>P</i>=0.027) and survivin expression (<i>r</i>=-0.198, <i>P</i>=0.015).
|
30863111 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we investigated the prognostic value of ARID1A for gastric cancer and its association with expression of PD-L1 and p53.
|
31043675 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
ENE was present in 36% of patients.EBV-positive carcinoma was evident in 5.8%, and p53 aberrant (chromosomal instable) tumors in 22.2%, a gastric cancer with deficient mismatch-repair status in 9%, and MSS/p53neg/EBVneg tumors were seen in 63% of patients.
|
31541339 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
OnclncRNA-626 promotes malignancy of gastric cancer via inactivated the p53 pathway through interacting with SRSF1.
|
31720086 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The molecular subtypes combining the CIMP and TP53 hot spot mutation status provide distinct clinicopathological features and prognostic impacts in GC.
|
30575210 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Solamargine increased the expression of long noncoding RNA (lnc) p53 induced transcript and lnc nuclear paraspeckle assembly transcript 1 (NEAT1)_2 (P<0.01) in GC by reducing the phosphorylation of extracellular signal‑regulated kinase (Erk)1/2 mitogen‑activated protein kinase (MAPK).
|
30864686 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Current evidence highlights the key function of SOX9 in GC and postulates it as a prognostic factor, novel biomarker for patient stratification and a promising target. gCSCs are critical targets for GC eradication and SOX9 is a regulator of gCSCs; hence, the inhibition of SOX9 is a potential therapeutic strategy for GC, particularly for the MSS/TP53+ subgroup of patients in whom SOX9 expression correlates with poor outcome.
|
30572738 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we evaluated prevalence of Her3 in gastric cancer, in a Saudi cohort of cases, along with its association with prognostic markers p53 and Ki-67.
|
30915908 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results show that CCNE1 amplification is significantly associated with liver metastasis in a TP53-mutated gastric cancer subtype.
|
31178228 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PKNOX2 suppresses gastric cancer through the transcriptional activation of IGFBP5 and p53.
|
30745575 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutations were highly recurrent (11/14; 79%) in MLH1-positive miGCs and were detected even in two microscopic lesions measuring 1 and 3 mm, respectively.
|
30474112 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The TP53 codon 72 Pro/Pro polymorphism may isolate a relatively high-risk patient group in T1N1M0/T2N0M0/T3N0M0 gastric cancer.
|
31578743 |
2019 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present study evaluated the potential of curcumin and resveratrol on p53 post-translational modifications during gastric cancer.
|
30055545 |
2018 |
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TP53 was shown to be upregulated in the H. pylori-positive group in both TCGA database and RNA sequencing data, which also showed higher expression in the GC tissues than in adjacent normal tissues (P < 0.05).
|
30175534 |
2018 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Functional loss of p53 cooperates with the in vivo microenvironment to promote malignant progression of gastric cancers.
|
29396430 |
2018 |
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The present study demonstrated that oridonin exhibited an anti-tumor effect on GC SNU-216 cells through regulating p53 expression and function.
|
30462771 |
2018 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, we demonstrated that the TP53 mutation itself could result in the depressed immune activities in GC and other cancer types.
|
30059832 |
2018 |
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer.
|
29725898 |
2018 |
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor.
|
30115935 |
2018 |